Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2023-03-09
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 55); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-29 (study day 186); relationship: N
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 209); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-05 (study day 405); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-05-29 (study day 429); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.